Triterpenoid antifungals for treating or preventing Pneumocystis spp. pneumonia
Enfumafungin derivatives like SCY-078 effectively address the limitations of current PCP treatments by inhibiting (1,3)-β-D-glucan synthase, providing safe and convenient oral therapy with high lung penetration and broad antifungal activity against Pneumocystis spp.
Patent Information
- Application Number
- JP2021549801
- Authority / Receiving Office
- JP · JP
- Patent Type
- Patents
- Current Assignee / Owner
- Priority Date
- 2019-02-27
- Filing Date
- 2020-02-25
- Publication Date
- 2024-11-12
- Estimated Expiration
- 2040-02-25
AI Technical Summary
Current treatments for Pneumocystis pneumonia (PCP) are limited, associated with significant toxicity, and face challenges with drug resistance and the need for long-term administration, which is often impractical due to the availability of drugs only in intravenous form and inadequate tissue penetration.
The use of enfumafungin derivatives, such as SCY-078, which inhibit (1,3)-β-D-glucan synthase, demonstrating high efficacy in reducing both cystic and vegetative forms of Pneumocystis spp. with adequate lung penetration and oral administration, allowing for safe and convenient long-term treatment.
SCY-078 achieves comparable efficacy to the current gold standard for PCP treatment, reducing both cystic and vegetative forms of Pneumocystis spp. with higher lung concentrations and better tolerability, making it a promising oral antifungal option for PCP prevention and treatment.
Smart Images

Figure 0007581219000015 
Figure 0007581219000016 
Figure 0007581219000017
Abstract
Description
[Technical field]
[0001] The present invention relates to the use of triterpenoid antifungal agents for treating and / or preventing Pneumocystis spp. pneumonia. More specifically, the present invention relates to the use of enfumafungin derivative triterpenoids (or pharma- ceutically acceptable salts or hydrates thereof), inhibitors of (1,3)-β-D-glucan synthesis resulting in a loss of (1,3)-β-D-glucan (a building block of fungal cell structure), in treating and / or preventing Pneumocystis spp. pneumonia. Currently available treatment options for Pneumocystis spp. pneumonia are limited and have significant associated toxicities. In contrast, the (1,3)-β-D-glucan synthase inhibitor ibrexafungelp (SCY-078) exhibits potent antifungal activity against Pneumocystis spp., exhibits adequate tissue penetration into the lungs, and is well tolerated. In accordance with the present invention, the use of ibrexafungelp can provide advantages in the treatment and / or prevention of Pneumocystis spp. pneumonia. [Background technology]
[0002] Fungal infections are a major medical problem and most commonly manifest as invasive or systemic mycoses (e.g., candidiasis, invasive aspergillosis), mucocutaneous infections (e.g., oral, esophageal and vulvovaginal candidiasis) and localized fungal infections (e.g., pneumonia, pleural empyema, and abscesses confined to the abdomen, brain, bone, etc.). The type and extent of infection depends on the virulence factors of the fungal pathogen, the host defenses and the anatomical area involved.
[0003] Severe systemic or invasive fungal infections are more common in immunocompromised patients, such as those undergoing chemotherapy to treat malignancies, or those receiving immunomodulatory agents to treat chronic inflammatory conditions, or those suffering from immunodeficiency due to acquired (e.g., AIDS) or genetic disorders. Despite currently available antifungal therapies, systemic fungal infections are associated with a mortality rate of up to 50%, depending on the pathogen and the patient's underlying condition.
[0004] Mucocutaneous fungal infections can occur in immunocompromised and non-immunocompromised individuals. The most common mucocutaneous fungal infection is vulvovaginal yeast infection, followed by oropharyngeal and esophageal candidiasis, which are mainly caused by Candida species.
[0005] Localized fungal infections can occur in immunocompromised and non-immunocompromised individuals and occur by fungi disseminating from the localized area where they normally colonize to normally sterile areas (e.g., intraperitoneal abscesses after intestinal perforation or surgery), or by fungi invading the blood or lymphatic system reaching specific organs (e.g., lungs, liver, spleen), or by acquisition from the environment (e.g., Pneumocystis spp. pneumonia) causing deep-seated infection.
[0006] Pneumocystis pneumonia (PCP) in humans is caused by the ubiquitous fungus Pneumocystis jirovecii, an opportunistic fungal organism that causes disease in immunocompromised individuals, particularly those infected with the human immunodeficiency virus (HIV). Although its prevalence has decreased with the advent of antiretroviral therapy (ART), PCP remains the most common opportunistic infection in patients with AIDS. Additionally, the growth of non-HIV immunocompromised populations (including bone marrow transplant recipients and solid organ transplant recipients), non-adherence to current therapies, the emergence of drug-resistant Pneumocystis jirovecii strains, and the increase in HIV+ cases in developing countries all make Pneumocystis a pathogen of continuing concern and a public health concern (Kelly MN, Shellito JE. Current understanding of Pneumocystis immunology. Future Microbiol. 2010 Jan;5(1):43-65).
[0007] Pneumocystis jirovecii was previously called Pneumocystis carinii, but the taxonomy of the organism has changed: P. carinii now properly refers only to the Pneumocystis species that infects rats, and P. jirovecii to the different species that infects humans. However, the abbreviation "PCP" is still used to indicate Pneumocystis pneumonia. The first infection with P. jirovecii usually occurs during early childhood: two-thirds of healthy children have antibodies against P. jirovecii by the age of 2 to 4 years. Rodent studies and case clusters in immunosuppressed patients suggest that Pneumocystis spreads through the air. Disease probably develops by new infection via the respiratory tract or by reactivation of latent infection. Before the widespread use of PCP prophylaxis and ART, PCP developed in 70%–80% of patients with AIDS; treated PCP courses were associated with a 20%–40% mortality rate in individuals with severe immunosuppression. Approximately 90% of PCP cases occurred in patients with CD4 T lymphocyte (CD4) cell counts below 200 cells / mm. The incidence of PCP has decreased, but mortality rates remain the same. Other factors associated with a higher risk of PCP include a lower CD4 cell percentage, previous episodes of PCP, oral candidiasis, recurrent bacterial pneumonia, unintentional weight loss, elevated plasma HIV RNA levels, and immunosuppressive therapy. The incidence of PCP has declined with the widespread use of PCP prophylaxis and ART, and most cases of PCP now occur in patients who are unaware of their HIV infection or not receiving ongoing HIV care and in patients with progressive immunosuppression due to other conditions (e.g., malignancy).
[0008] The most common symptoms of PCP are subacute onset of progressive dyspnea, fever, dry cough, and chest discomfort that worsen within days to weeks and may result in fatal respiratory failure, although rapidly progressive fulminant pneumonia may also develop. Because blood tests and chest x-rays are not pathognomonic for PCP (and because the organism cannot be routinely cultured), a definitive diagnosis of PCP requires histopathological or cytopathological or molecular demonstration of the organism in a tissue sample, a bronchoalveolar lavage (BAL) fluid sample, or an induced saliva sample.
[0009] Treatment with antibacterial agents active against Pneumocystis should be initiated as soon as the diagnosis is made. Because the disease has potentially fatal consequences, immunocompromised patients at high risk of developing this infection often receive prophylactic antibiotic treatment (prophylaxis) while at risk, which can be several months. Trimethoprim-sulfamethoxazole (TMP-SMX), also written as trimethoprim / sulfamethoxazole (TMP / SMX), is the currently recommended antibacterial agent to prevent and treat PCP. However, there is a high incidence of intolerance to this drug, and serious, sometimes life-threatening, adverse reactions have been reported after the use of TMP-SMX. These undesirable reactions often lead to the interruption or permanent discontinuation of TMP-SMX. There is a high incidence of adverse reactions to TMP-SMX in patients with HIV (20%-85% of patients). Common adverse effects are rash (30%-55% of patients) (including Stevens-Johnson syndrome), fever (30%-40% of patients), leukopenia (30%-40% of patients), thrombocytopenia (15% of patients), azotemia (1%-5% of patients), hepatitis (20% of patients), and hyperkalemia (Guidelines for the Prevention and Treatment of Opportunistic Infections in Adults and Adolescents with HIV, Pneumocystis Pneumonia, Last Updated: March 28, 2019; Last Reviewed: June 26, 2019. https: / / aidsinfo.nih.gov / guidelines / html / 4 / adult-and-adolescent-opportunistic-infection / 321 / pneumocystis-pneumonia.). Alternative therapies exist when TMP-SMX is not tolerated, but such therapies have not shown the same efficacy in all settings and are associated with significant toxicities.The most common adverse effects of alternative therapies include: methemoglobinemia and hemolysis (especially in patients with G6PD deficiency) with dapsone or primaquine; rash and fever with dapsone; azotemia, pancreatitis, hypo- or hyperglycemia, leukopenia, electrolyte abnormalities, and cardiac arrhythmias with pentamidine; anemia, rash, fever, and diarrhea with primaquine and clindamycin; and headache, nausea, diarrhea, rash, and transaminase elevations with atovaquone.
[0010] Furthermore, non-adherence to treatment and / or long-term prophylactic use in individuals colonized with Pneumocystis has led to the selection of mutations that give rise to drug-resistant strains. These include mutations in the targets of trimethoprim and pyrimethamine, atovaquone and sulfa drugs, leading to treatment failure and increased mortality (Kelly MN, Shellito JE. Current understanding of Pneumocystis immunology. Future Microbiol. 2010 Jan;5(1):43-65). As drug resistance threatens the most effective existing treatments, new therapies are greatly needed.
[0011] Pneumocystis spp., previously classified as protozoa, are yeast-like fungi that reside extracellularly within the alveoli and can infect mammals, where P. jirovecii infects humans, P. carinii infects rats, and P. murina infects mice. In contrast to other fungi, Pneumocystis cannot be cultured in vitro in typical fungal growth media, and most of what is known about its life cycle comes from observations in animal models of infection. The inability to culture the organism in vitro is a major obstacle in investigating treatments for this opportunistic infection, and most studies rely on in vivo observations. Within the mammalian host, Pneumocystis has a tropism for the alveoli. Microscopic observations and molecular genetic studies suggest a life cycle that involves an asexual mode of replication via binary fission in an amoeboid trophozoite (vegetative) form and a sexual mode that results in the formation of asci (cysts) containing eight ascospores.
[0012] PCP currently has limited treatment options. Standard antifungal drugs that target ergosterol and ergosterol biosynthesis, such as amphotericin B and the azoles, are ineffective. Echinocandins (caspofungin, anidulafungin, and micafungin) inhibit the synthesis of (1,3)-β-D-glucan, an essential component of the cell wall of many fungi, including the cystic forms of Pneumocystis spp. However, reports of the efficacy of echinocandins for PCP in patients reveal uncertainties and limitations of this class of drugs. A mouse model evaluating the activity of echinocandins against mouse PCP (Cushion MT, Linke MJ, Ashbaugh A, Sesterhenn T, Collins MS, Lynch K, Brubaker R, Walzer PD. Echinocandin treatment of pneumocystis pneumonia in rodent models depletes cysts leaving trophic burdens that cannot transmit the infection. PLoS One. 2010 Jan 29;5(1):e8524) showed that parenteral (intraperitoneal) administration of echinocandins for 3 weeks significantly reduced cyst burden compared to untreated mice. No dose response was observed for any of the echinocandins. In contrast to the marked reduction in cysts, numerous trophic forms remained in the lungs of treated mice, often reaching levels that were not significantly different from untreated controls. The response to each echinocandin was different, with caspofungin being the most effective and micafungin the least effective, with micafungin not showing a significant reduction in nutrient burden at any dose compared to untreated control mice. These observations suggest that echinocandins may have an effect on the cystic form of Pneumocystis spp., but that their effect on the vegetative form of the fungus is less clear and is probably compound specific.
[0013] Although echinocandins are not currently indicated for the treatment or prevention of PCP, isolated reports have documented their use in clinical practice, mostly as salvage therapy alone or in combination with TMP-SMX (with mixed results), highlighting the importance of developing new antifungal agents to treat this fungal infection (Zhang G et al. Efficacy of caspofungin combined with trimethoprim / sulfamethoxazole as first-line therapy to treat non-HIV patients with severe pneumocystis pneumonia. Exp Ther Med. 2018 Feb;15(2):1594-1601.; Huang YS et al. Echinocandins as alternative treatment for HIV-infected patients with Pneumocystis pneumonia. AIDS. 2019 Jul 1;33(8):1345-1351.). Another limitation of echinocandins as a potential alternative for the treatment or prevention of PCP is that they are only available in the form of intravenous injections, and that treatment or prevention of PCP often requires weeks or months of treatment. Prolonged IV administration is suboptimal and often not feasible. Furthermore, consistent with the low distribution volumes reported for the three echinocandins (in the range of 0.15-0.8 liters / kg), tissue concentrations achieved in the lungs are usually lower than plasma concentrations (Felton T, Troke PF, Hope WW. Tissue penetration of antifungal agents. Clin Microbiol Rev. 2014 Jan;27(1):68-88), which may result in less than effective concentrations at the site of infection (i.e., lungs).
[0014] Enfumafungin is a hemiacetal triterpene glycoside produced in the fermentation of Hormonema spp. on living leaves of Juniperus communis (U.S. Pat. No. 5,756,472; Pelaez et al., Systematic and Applied Microbiology, 23:333-343 (2000); Schwartz et al., JACS, 122: 4882-4886 (2000); Schwartz, RE, Expert Opinion on Therapeutic Patents, 11(11): 1761-1772 (2001)). Enfumafungin is one of several triterpene glycosides with in vitro antifungal activity. The antifungal mechanism of action of enfumafungin and other antifungal triterpenoid glycosides has been identified as inhibition of fungal cell wall glucan synthesis due to its specific activity against (1,3)-β-D-glucan synthase (Onishi et al., Antimicrobial Agents and Chemotherapy, 44: 368-377 (2000); Pelaez et al., (2000)). 1,3-β-D-glucan synthase remains an attractive target for antifungal drug action because it is present in many types of pathogenic fungi, thus providing a broad antifungal spectrum. In addition, since there is no mammalian equivalent of 1,3-β-D-glucan synthase, the enfumafungin derivatives described herein have little or no mechanism-based toxicity. The triterpenoid compound derivatives of enfumafungin used in accordance with the present invention exhibit activity against fungal isolates of Candida spp., including isolates resistant to azole or other glucan synthase inhibitors (e.g., lipopeptides such as echinocandins), indicating that the biological and molecular targets of the enfumafungin derivatives are distinct from those of other glucan synthase inhibitors.
[0015] Various enfumafungin derivatives have been disclosed, for example, in WO 2007 / 126900 and WO 2007 / 127012.
[0016] Certain representatives of these enfumafungin derivatives can be administered orally and have demonstrated antifungal activity against Candida species and Aspergillus species, as well as appropriate distribution to tissues, including lung tissue (Wring S, Borroto-Esoda K, Solon E, Angulo D. 2019. SCY-078, a novel fungicidal agent, demonstrates distribution to tissues associated with fungal infections during mass balance studies with intravenous and oral [ 14 C]SCY-078 in albino and pigmented rats. Antimicrob Agents Chemother 63:e02119-18. https: / / doi.org / 10.1128 / AAC.02119-18.).
[0017] The ability of antifungal drugs to distribute into lung tissue is relevant for the treatment or prevention of PCP. The ability of SCY-078, a representative compound of the enfumafungin derivatives described herein, to distribute into lung tissue was evaluated in an animal model. Id. Male albino Wistar Han (WH; Charles River, Raleigh, NC) (n=38) or male (n=18) and female (n=3) pigmented Long-Evans (LE; Hilltop Lab Animals, Inc., Scottdale, PA) rats were administered [14C]SCY-078 by oral administration (15 mg / kg, approximately 150 μCi / kg, in 0.5% aqueous methylcellulose) or iv as a 1-hour infusion (10 mL / kg / h) (5 mg / kg, approximately 108 μCi / kg, 7.5:1 molar ratio of Captisol:SCY-078 in saline). WH rats were used for mass balance and pharmacokinetic (PK) measurements after iv and oral administration, and both WH and LE rats were used for quantitative whole-body autoradiography (QWBA) measurements. Dose levels were selected to reflect a clinically relevant target exposure of 11.2 μg·h / mL for Candida spp. infections. Concentration, homogeneity, radioactive purity, and stability of the dose formulation were confirmed to be acceptable prior to administration. For QWBA whole-body sections (approximately 40 μm thick with a Leica CM3600 cryomicrotome; Nussloch, Germany) in which all major tissues, organs, and fluids were represented, sections were exposed for phosphorus imaging (Fuji Biomedical, Stamford, CT) along with calibration standards. Animals were deeply anesthetized with isoflurane anesthesia, and blood samples were taken before euthanasia by freezing in a hexane / solid carbon dioxide bath for at least 15 min. Imaging plates were scanned with a GE Healthcare Typhoon FLA 9500 image acquisition system (GE / Molecular Dynamics, Sunnyvale, CA).Quantification was performed by image densitometry using MCID image analysis software (v.7.0; Interfocus Imaging Ltd., Linton, Cambridge, UK) and standard curves were constructed from integrated responses (molecular dynamics counts [MDC] / mm2) and nominal concentrations of 14C calibration standards. Concentrations of radioactivity were expressed as [14C]SCY-078 μg equivalents / g tissue. The lower limits of quantification were 0.024 and 0.049 μg equivalents per gram of tissue for iv and oral administration of SCY-078, respectively.
[0018] Male pigmented Long-Evans rats were 14 The tissue-to-blood AUC ratios of total radioactivity following oral administration of 15 mg / kg [C]-SCY-078 are shown below: [Table 1]
[0019] In this study, the exposure observed in the lung was more than 20-fold higher than that measured in plasma.
[0020] The safety and tolerability of SCY-078 has been evaluated in over 900 subjects in approximately 20 clinical trials at various doses and treatment durations, including up to one year of administration. The most common adverse events were mild to moderate transient gastrointestinal disturbances, such as nausea, diarrhea, and abdominal pain. Serious adverse events potentially related to SCY-078 were very rare, with few interruptions or discontinuations of treatment due to adverse reactions. Furthermore, the safety profile of oral SCY-078 has been evaluated in standard long-term nonclinical toxicity studies, including nine months of administration in dogs and six months of administration in rats, according to ICH guidelines, at doses and exposures higher than would be expected in humans. Results from these nonclinical studies support the long-term administration of oral SCY-078 in humans. SCY-078 is currently being evaluated in ongoing clinical trials for the treatment of fungal infections, such as candidiasis and aspergillosis. SCY-078 has not yet been evaluated in clinical trials for the treatment or prevention of PCP. [Prior art documents] [Patent documents]
[0021] [Patent Document 1] U.S. Patent No. 5,756,472 [Patent Document 2] International Patent Publication No. 2007 / 126900 [Patent Document 3] International Patent Publication No. 2007 / 127012 [Non-patent literature]
[0022] [Non-Patent Document 1] Kelly MN, Shellito JE. Current understanding of Pneumocystis immunology. Future Microbiol. 2010 Jan;5(1):43-65 [Non-Patent Document 2] Guidelines for the Prevention and Treatment of Opportunistic Infections in Adults and Adolescents with HIV, Pneumocystis Pneumonia, Last Updated: March 28, 2019; Last Reviewed: June 26, 2019. https: / / aidsinfo.nih.gov / guidelines / html / 4 / adult-and-adolescent-opportunistic-infection / 321 / pneumocystis-pneumonia. Non-Patent Document 3 Kelly MN, Shellito JE. Current understanding of Pneumocystis immunology. Future Microbiol. 2010 Jan;5(1):43-65 Non-Patent Document 4 Cushion MT, Linke MJ, Ashbaugh A, Sesterhenn T, Collins MS, Lynch K, Brubaker R, Walzer PD. Echinocandin treatment of pneumocystis pneumonia in rodent models depletes cysts leaving trophic burdens that cannot transmit the infection. PLoS One. 2010 Jan 29;5(1):e8524 Non-Patent Document 5 Zhang G et al. Efficacy of caspofungin combined with trimethoprim / sulfamethoxazole as first-line therapy to treat non-HIV patients with severe pneumocystis pneumonia. Exp Ther Med. 2018 Feb;15(2):1594-1601
Non-licensed Document 6
Non-licensed Document 7
Non-licensed literature 9
Non-licensed literature 10
Non-licensed Document 11
Non-licensed Document 12
Non-licensed Document 13
[0023] Given the limited number of antibiotics available to treat or prevent PCP, the significant and sometimes life-threatening toxicity of currently approved compounds, and the increasing incidence of P. jirovecii resistance to currently available antibiotic options, there is a need in the art for antifungal therapies that are effective in treating and preventing PCP in humans and that can be safely and conveniently administered over the often prolonged treatment periods required to prevent and treat this infection. [Means for solving the problem]
[0024] The triterpenoid compound SCY-078 or ibrexafungelp derived from enfumafungin (a representative compound of the enfumafungin derivatives described herein) shows a high level of efficacy in treating and / or preventing PCP in mouse models. SCY-078 exhibits potent antifungal activity against Pneumocystis spp., exhibits adequate tissue penetration to the lung, and is well tolerated. According to the present invention, SCY-078 or ibrexafungelp can be used to treat and / or prevent Pneumocystis spp. pneumonia in humans.
[0025] Unexpectedly, SCY-078 showed pharmacological activity comparable to that of the positive control Bactrim® (trimethoprim / sulfamethoxazole), the current gold standard for the treatment of PCP. More surprisingly, the compound showed a reduction in both cyst (ascus) and vegetative (nucleate) loads. The life cycle of Pneumocystis spp. exists in two forms: cyst and vegetative. The cyst form has a cell wall that contains (1,3)-β-D-glucan, a feature that is absent in the vegetative form. Although the role of each form of the fungus (cyst and vegetative) in human disease is not fully understood, it is believed that inhibition of both forms is optimal to control PCP infection and prevent dissemination. According to the present invention, SCY-078, as an inhibitor of (1,3)-β-D-glucan synthase, provided a pharmacological effect on the cyst form (e.g., reduction in cyst load). Surprisingly, treatment with SCY-078 also resulted in a significant reduction in nuclei (nuclei represent nutrient load). Furthermore, reductions in cystic and nutrient morphology occurred in both preventive and therapeutic models of PCP.
[0026] The compound unexpectedly showed enhanced lung penetration when compared to other (1,3)-β-D-glucan synthase inhibitors. SCY-078 can be administered orally, which offers an advantage in the prevention and treatment of PCP, given that PCP typically requires long-term antifungal therapy.
[0027] The present invention relates to the use of enfumafungin derivatives for treating and / or preventing PCP. Enfumafungin derivatives and their pharma- ceutically acceptable salts or hydrates are useful in inhibiting (1,3)-β-D-glucan synthase, and are particularly useful in treating and / or preventing PCP, an infectious disease for which there is a need in the art for potent antifungal activity.
[0028] The present invention addresses the needs in the art as described above, because the enfumafungin derivatives described herein (a) achieved unexpectedly high efficacy in the treatment and prevention of PCP, (b) exhibited activity against both forms (cystic and vegetative) of Pneumocystis jirovecii, (c) surprisingly achieved several-fold higher concentrations in the lungs compared to in the plasma, (d) can be administered orally, thereby allowing optimal treatment of these infections that often require months of treatment, and (e) are well tolerated, thereby allowing safe administration over extended periods of time.
[0029] Utilities of the present invention include, but are not limited to, the ability to more easily achieve successful results in the treatment and / or prevention of PCP for the reasons outlined above.
[0030] The present invention relates to a compound of formula (I): [ka]
[0031] [During the ceremony, X is O or H, H; R e is C(O)NR f R g or a 6-membered heteroaryl group containing 1 or 2 nitrogen atoms, which heteroaryl group is optionally monosubstituted at a ring carbon with fluoro or chloro or monosubstituted at a ring nitrogen with oxygen; R f , R g , R 6 and R 7 are each independently hydrogen or C 1 -C 3 is alkyl; R 8 is C 1 -C 4 Alkyl, C 3 -C 4 Cycloalkyl or C 4 -C 5 cycloalkyl-alkyl; R 9 is methyl or ethyl; and R 8 and R 9 may together form a six-membered saturated ring containing one oxygen atom. or a pharma- ceutically acceptable salt or hydrate thereof.
[0032] The present invention further provides a method of treating and / or preventing PCP in a subject, the method being by administering a compound of formula (I) or a pharma- ceutically acceptable salt or hydrate thereof.The present invention further provides the use of a compound of formula (I) or a pharma- ceutically acceptable salt or hydrate thereof in the preparation of a medicament for treating and / or preventing PCP in a subject.
[0033] According to the present invention, triterpenoid antifungal agents derived from enfumafungin are capable of reducing both nutrient burden (as evidenced by reduced nuclei) and cyst burden (as evidenced by reduced asci) in a Pneumocystis spp. model of infection. [Brief description of the drawings]
[0034] [Figure 1] FIG. 1 is a graph of the log10 mean nuclei and log10 mean asci after the 6-week study, showing that prophylactic administration of SCY-078 resulted in a statistically significant reduction in both nuclei and asci when compared to untreated controls. [Diagram 2] FIG. 2 is a graph of the log10 mean number of nuclei and the log10 mean number of asci after 7, 14 and 21 days of treatment with SCY-078 compared to untreated controls and TMP / SMX. [Diagram 3] FIG. 3 is a graph of the log10 mean number of nuclei and the log10 mean number of asci after 28, 35, and 42 days of treatment with SCY-078 compared to untreated controls and TMP / SMX. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0035] The present invention relates to the use of enfumafungin derivative triterpenoid antifungal compounds for treating and / or preventing Pneumocystis spp. pneumonia. More specifically, the present invention relates to the use of enfumafungin derivative triterpenoids (or pharma- ceutically acceptable salts or hydrates thereof), which are inhibitors of (1,3)-β-D-glucan synthesis, in treating and / or preventing PCP, a disease in which adequate tolerance to long-term antifungal therapy (more than 4 weeks) is required, reduction of the cystic and nuclear load of P. jirovecii is desirable, and adequate penetration of the antifungal agent into the infected tissue is required. The present invention provides a needed and advantageous alternative to trimethoprim / sulfamethoxazole (TMP / SMX), which is currently considered the treatment of choice for PCP but is limited by significant toxicity associated with its use (several other currently available options also have significant safety concerns). The enfumafungin derivative triterpenoids described herein exhibit potent antifungal activity against Pneumocystis spp., demonstrate adequate tissue penetration to the lung, and are well tolerated, thereby offering advantages in the treatment and / or prevention of Pneumocystis spp. pneumonia.
[0036] The present invention relates to a compound of formula (I): [ka]
[0037] [During the ceremony, X is O or H, H; R e is C(O)NR f R gor a 6-membered heteroaryl group containing 1 or 2 nitrogen atoms, which heteroaryl group is optionally monosubstituted at a ring carbon with fluoro or chloro or monosubstituted at a ring nitrogen with oxygen; R f , R g , R 6 and R 7 are each independently hydrogen or C 1 -C 3 is alkyl; R 8 is C 1 -C 4 Alkyl, C 3 -C 4 Cycloalkyl or C 4 -C 5 cycloalkyl-alkyl; R 9 is methyl or ethyl; and R 8 and R 9 may together form a six-membered saturated ring containing one oxygen atom. or a pharma- ceutically acceptable salt or hydrate thereof.
[0038] The present invention further provides a method of treating and / or preventing PCP in a subject, the method being by administering a compound of formula (I) or a pharma- ceutically acceptable salt or hydrate thereof.The present invention further provides the use of a compound of formula (I) or a pharma- ceutically acceptable salt or hydrate thereof in the preparation of a medicament for treating and / or preventing PCP in a subject.
[0039] The present invention further relates to a compound of formula (Ia): [ka]
[0040] wherein the substituents are as given in formula (I). or a pharma- ceutically acceptable salt or hydrate thereof.
[0041] The present invention further provides a method of treating and / or preventing PCP in a subject, the method being by administering a compound of formula (Ia) or a pharma- ceutically acceptable salt or hydrate thereof.The present invention further provides the use of a compound of formula (Ia) or a pharma- ceutically acceptable salt or hydrate thereof in the preparation of a medicament for treating and / or preventing PCP in a subject.
[0042] In embodiment 1: X is H, H, and the other substituents are as provided in formula (I).
[0043] In embodiment 2: R e is pyridyl or pyrimidinyl, wherein the pyridyl or pyrimidinyl is optionally monosubstituted at a ring carbon with fluoro or chloro, or monosubstituted at a ring nitrogen with oxygen, and the other substituents are as given in embodiment 1 or formula (I).
[0044] In embodiment 3: R e is 4-pyridyl, and the other substituents are as given in embodiment 1 or formula (I).
[0045] In embodiment 4: R e is C(O)NH 2 or C(O)NH(C 1 -C 3 alkyl), and the other substituents are as provided in embodiment 1 or formula (I).
[0046] In embodiment 5: R 8 is C 1 -C 4 alkyl, and R 9is methyl; and the other substituents are as provided in embodiment 1, embodiment 2, embodiment 3 or embodiment 4 or in formula (I).
[0047] In embodiment 6: R 8 is t-butyl, R 9 is methyl; and the other substituents are as provided in embodiment 1, embodiment 2, embodiment 3 or embodiment 4 or in formula (I).
[0048] In embodiment 7: R 6 and R 7 are each independently hydrogen or methyl, and the other substituents are as provided in embodiment 1, embodiment 2, embodiment 3, embodiment 4, embodiment 5 or embodiment 6 or formula (I).
[0049] In embodiment 1': X is H, H, and the other substituents are as provided in formula (Ia).
[0050] In embodiment 2': R e is pyridyl or pyrimidinyl, wherein the pyridyl or pyrimidinyl is optionally monosubstituted at a ring carbon with fluoro or chloro, or monosubstituted at a ring nitrogen with oxygen, and the other substituents are as given in embodiment 1' or formula (Ia).
[0051] In embodiment 3': R e is 4-pyridyl, and the other substituents are as given in embodiment 1' or formula (Ia).
[0052] In embodiment 4': R e is C(O)NH 2 or C(O)NH(C 1 -C 3 alkyl), and the other substituents are as provided in embodiment 1' or formula (Ia).
[0053] In embodiment 5': R 8 is C 1 -C 4 alkyl, and R 9 is methyl; and the other substituents are as given in embodiment 1', embodiment 2', embodiment 3' or embodiment 4' or in formula (Ia).
[0054] In embodiment 6': R 8 is t-butyl, R 9 is methyl; and the other substituents are as given in embodiment 1', embodiment 2', embodiment 3' or embodiment 4' or in formula (Ia).
[0055] In embodiment 7': R 6 and R 7 are each independently hydrogen or methyl, and the other substituents are as provided in embodiment 1', embodiment 2', embodiment 3', embodiment 4', embodiment 5' or embodiment 6' or formula (Ia).
[0056] In a preferred embodiment, the present invention provides a compound according to the present invention comprising a compound of formula (II): [ka]
[0057] (which is (1S,4aR,6aS,7R,8R,10aR,10bR,12aR,14R,15R)-15-[[2-amino-2,3,3-trimethylbutyl]oxy]-8-[(1R)-1,2-dimethylpropyl]-14-[5-(4-pyridinyl)-1H-1,2,4-triazol-1-yl]-1,6,6a,7,8,9,10,10a,10b,11,12,12a-dodecahydro-1,6a,8,10a-tetramethyl-4H-1,4a-propano-2H-phenanthro[1,2-c]pyran-7-carboxylic acid) or a pharma- ceutically acceptable salt or hydrate thereof.
[0058] The present invention further provides a method of treating and / or preventing PCP in a subject, the method being by administering a compound of formula (II) or a pharma- ceutically acceptable salt or hydrate thereof.The present invention further provides the use of a compound of formula (II) or a pharma- ceutically acceptable salt or hydrate thereof in the preparation of a medicament for treating and / or preventing PCP in a subject.
[0059] In another preferred embodiment, the present invention provides a compound of formula (IIa): [ka]
[0060] (herein referred to as SCY-078 or ibrexafungerp) (which is (1S,4aR,6aS,7R,8R,10aR,10bR,12aR,14R,15R)-15-[[(2R)-2-amino-2,3,3-trimethylbutyl]oxy]-8-[(1R)-1,2-dimethylpropyl]-14-[ 5-(4-pyridinyl)-1H-1,2,4-triazol-1-yl]-1,6,6a,7,8,9,10,10a,10b,11,12,12a-dodecahydro-1,6a,8,10a-tetramethyl-4H-1,4a-propano-2H-phenanthro[1,2-c]pyran-7-carboxylic acid) or a pharma- ceutically acceptable salt or hydrate thereof.
[0061] The present invention further provides a method of treating and / or preventing PCP in a subject, the method being by administering a compound of formula (IIa) or a pharma- ceutically acceptable salt or hydrate thereof.The present invention further provides the use of a compound of formula (IIa) or a pharma- ceutically acceptable salt or hydrate thereof in the preparation of a medicament for treating and / or preventing PCP in a subject.
[0062] In a preferred embodiment, a phosphate salt of a compound of Formula (I), Formula (Ia), Formula (II) or Formula (IIa) is used or administered as described herein.
[0063] In a preferred embodiment, the citrate salt of a compound of Formula (I), Formula (Ia), Formula (II) or Formula (IIa) is used or administered as described herein.
[0064] In a preferred embodiment, the compounds of Formula (I), Formula (Ia), Formula (II) and Formula (IIa) or a pharma- ceutically acceptable salt or hydrate form thereof are administered orally.
[0065] In a preferred embodiment, the compounds of Formula (I), Formula (Ia), Formula (II) and Formula (IIa) or a pharma- ceutically acceptable salt or hydrate form thereof are administered intravenously.
[0066] The present invention further provides the use of a pharmaceutical composition comprising a compound of Formula (I), Formula (Ia), Formula (II) or Formula (IIa) or a pharma- ceutically acceptable salt or hydrate thereof and a pharma- ceutically acceptable carrier, adjuvant or vehicle for treating and / or preventing PCP in a subject.
[0067] The present invention further provides a method of treating and / or preventing PCP in a subject, wherein the method is by administering a pharmaceutical composition comprising a compound of Formula (I), Formula (Ia), Formula (II) or Formula (IIa) or a pharma- ceutically acceptable salt or hydrate thereof and a pharma- ceutically acceptable carrier, adjuvant or vehicle.
[0068] The present invention provides a method for treating and / or preventing PCP, the method comprising administering an effective amount of a compound of Formula (I), Formula (Ia), Formula (II) or Formula (IIa) (or a pharma- ceutically acceptable salt or hydrate thereof).
[0069] In the descriptions of compounds in the embodiments described above, the indicated substitutions are included only to the extent that the substituents result in stable compounds consistent with the definition.
[0070] The compounds of Formula (I), Formula (Ia), Formula (II) and Formula (IIa) and their pharma- ceutically acceptable salts and hydrate forms exhibit antibacterial (e.g., antifungal) activity against yeast and other fungi, including one or more of the following: Acremonium, Absidia (e.g., Absidia corymbifera), Alternaria, Aspergillus (e.g., Aspergillus clavatus, Aspergillus flavus, Aspergillus fumigatus, Aspergillus nidulans, Aspergillus niger ... niger, Aspergillus terreus, and Aspergillus versicolor), Bipolaris, Blastomyces (e.g., Blastomyces dermatitidis), Blastoschizomyces (e.g., Blastoschizomyces capitatus), Candida (e.g., Candida albicans, Candida auris, Candida glabrata, Candida guilliermondii, Candida kefir, Candida kefyr, Candida krusei, Candida lusitaniae, Candida parapsilosis, Candida pseudotropicalis, Candida stellatoidea, Candida tropicalistropicalis, Candida utilis, Candida lipolytica, Candida famata, and Candida rugosa), Cladosporium (e.g., Cladosporium carrionii and Cladosporium trichloides), Coccidioides (e.g., Coccidioides immitis), Cryptococcus (e.g., Cryptococcus neoformans), neoformans), Curvularia, Cunninghamella (e.g., Cunninghamella elegans), Dermatophyte, Exophiala (e.g., Exophiala dermatitidis and Exophiala spinifera), Epidermophyton (e.g., Epidermophyton floccosum), Fonsecaea (e.g., Fonsecaea pedrosoi), Fusarium (e.g., Fusarium solani), solani), Geotrichum (e.g., Geotrichum candidum and Geotrichum clavatum), Histoplasma (e.g., Histoplasma capsulatum var.capsulatum), Malassezia (e.g., Malassezia furfur), Microsporum (e.g., Microsporum canis and Microsporum gypseum), Mucor, Paracoccidioides (e.g., Paracoccidioides brasiliensis), Penicillium (e.g., Penicillium marneffei), Phialophora, Pityrosporum ovale ovale, Pneumocystis (e.g., Pneumocystis jirovecii), Pseudallescheria (e.g., Pseudallescheria boydii), Rhizopus (e.g., Rhizopus microsporus var. rhizopodiformis and Rhizopus oryzae), Saccharomyces (e.g., Saccharomyces cerevisiae), Scedosporium (e.g., Scedosporium apiospermum), apiosperum), Scopulariopsis, Sporothrix (e.g., Sporothrix schenckii), Trichoderma, Trichophyton (e.g., Trichophyton mentagrophytes, and Trichophyton rubrum),rubrum), and Trichosporon (e.g., Trichosporon asahii, Trichosporon beigelii, and Trichosporon cutaneum).
[0071] The compounds of Formula (I), Formula (Ia), Formula (II) and Formula (IIa) and their pharma- ceutically acceptable salts and hydrate forms can be prepared according to the synthetic methods disclosed in U.S. Pat. No. 8,188,085, the contents of which are incorporated herein by reference in their entirety.
[0072] As used herein, the term "alkyl" refers to any straight or branched chain alkyl group having a number of carbon atoms in the specified range. Thus, for example, "C 1-6 Alkyl" (or "C 1 -C 6 "Alkyl") refers to all isomeric forms of hexyl alkyl and pentyl alkyl, as well as n-, iso-, sec- and t-butyl, n- and isopropyl, ethyl and methyl. 1-4 "Alkyl" refers to n-, iso-, sec- and t-butyl, n- and isopropyl, ethyl and methyl.
[0073] The term "cycloalkyl" refers to any cyclic ring of an alkane having a number of carbon atoms in the specified range. Thus, for example, "C 3-4 Cycloalkyl" (or "C 3 -C 4 "Cycloalkyl") refers to cyclopropyl and cyclobutyl.
[0074] The term "cycloalkyl-alkyl" (or, equivalently, "alkyl-cycloalkyl"), as used herein, refers to a system containing an alkyl portion as described above and also containing a cycloalkyl portion as described above. The bond to the "cycloalkyl-alkyl" (or "alkyl-cycloalkyl") can be through either the cycloalkyl portion or the alkyl portion. The number of carbon atoms specified in a "cycloalkyl-alkyl" system refers to the total number of carbon atoms in both the alkyl and cycloalkyl portions. 4 -C 5 Examples of cycloalkyl-alkyl include, but are not limited to, methylcyclopropyl, dimethylcyclopropyl, methylcyclobutyl, ethylcyclopropyl, cyclopropylmethyl, cyclopropylethyl, and cyclobutylmethyl.
[0075] The term "halogen" (or "halo") refers to fluorine, chlorine, bromine, and iodine (alternatively referred to as fluoro, chloro, bromo, and iodo).
[0076] As used herein, the term "or" refers to alternatives, which may be combined where appropriate.
[0077] Unless otherwise specified, all ranges described herein are inclusive. For example, a heterocyclic ring described as containing "1-4 heteroatoms" means that the ring may contain 1, 2, 3, or 4 heteroatoms. Any range described herein should also be understood to include within its scope all subranges within that range. Thus, for example, a heterocyclic ring described as containing "1-4 heteroatoms" is intended to include, in its embodiments, heterocyclic rings containing 2-4 heteroatoms, 3 or 4 heteroatoms, 1-3 heteroatoms, 2 or 3 heteroatoms, 1 or 2 heteroatoms, 1 heteroatom, 2 heteroatoms, etc.
[0078] The various cycloalkyl and heterocyclic / heteroaryl rings and heterocyclic / heteroaryl ring systems defined herein can all be attached to the remainder of the compound at any ring atom (i.e., any carbon atom or any heteroatom) provided that a stable compound is obtained. Suitable 5- or 6-membered heteroaromatic rings include, but are not limited to, pyridyl, pyrazinyl, pyrimidinyl, pyridazinyl, and triazolyl.
[0079] A "stable" compound is one that can be prepared and isolated, and whose structure and properties remain essentially unchanged or can be made to remain unchanged for a sufficient period of time to permit the compound to be used for the purposes described herein (e.g., therapeutic or prophylactic administration to a subject). When a compound is referred to, the reference also encompasses stable complexes (e.g., stable hydrates) of the compound.
[0080] As a result of the selection of substituents and substituent patterns, certain of the compounds represented by formula (I), formula (Ia), formula (II) and formula (IIa) may have asymmetric centers and may exist as mixtures of stereoisomers or as individual diastereomers or enantiomers. Unless otherwise indicated, all isomeric forms of these compounds (as well as their pharma-ceutically acceptable salts and hydrate forms), whether isolated or in admixture, are within the scope of the present invention. Also included within the scope of the present invention are the tautomeric forms of the compounds (as well as their pharma-ceutically acceptable salts and hydrate forms).
[0081] When any variable occurs more than one time in any constituent or in Formula (I), Formula (Ia), Formula (II) or Formula (IIa), its definition at each occurrence is independent of its definition at every other occurrence, and combinations of substituents and / or variables are permissible only if such combinations result in stable compounds.
[0082] The term "substituted" includes mono- and polysubstitution with a named substituent, to the extent that such mono- and polysubstitution (including multiple substitutions at the same site) is chemically possible. Unless otherwise specified, substitution with a named substituent is permitted on any atom in a ring (e.g., aryl, cycloalkyl, heteroaryl, or heterocyclyl), provided that such ring substitution is chemically possible and results in a stable compound.
[0083] A bond ending in a wavy line is used herein to indicate the point of attachment of a substituent or moiety. This usage is illustrated by the following example: [ka]
[0084] The compounds of formula (I), formula (Ia), formula (II) and formula (IIa) and their pharma- ceutically acceptable salts and hydrates are also useful in the preparation and execution of screening assays for antifungal compounds. For example, the compounds are useful for isolating mutants that are excellent screening tools for identifying additional antifungal compounds.
[0085] The compounds of formula (I), formula (Ia), formula (II) and formula (IIa) can be administered in the form of a "pharmaceutical acceptable salt" or hydrate, where appropriate. However, other salts may be useful in the preparation of the compounds or their pharmaceutical acceptable salts. For example, when the compounds contain a basic amine group, they can be conveniently isolated as trifluoroacetate salts (e.g., by HPLC purification). The conversion of the trifluoroacetate salt to another salt, including a pharmaceutical acceptable salt, can be accomplished by many standard methods known in the art. For example, a suitable ion exchange resin can be used to generate the desired salt. Alternatively, the conversion of the trifluoroacetate salt to the parent compound free amine can be accomplished by standard methods known in the art (e.g., NaHCO 3The other desired amine salts can then be prepared in a conventional manner by reacting the free base with a suitable organic or inorganic acid. Representative pharma- ceutically acceptable quaternary ammonium salts include the following: hydrochloride, sulfate, phosphate, carbonate, acetate, tartrate, citrate, malate, succinate, lactate, stearate, fumarate, hippurate, maleate, gluconate, ascorbate, adipate, gluceptate, glutamate, glucoronate, propionate, benzoate, mesylate, tosylate, oleate, lactobioate, lauryl sulfate, besylate, caprylate, isethionate, gentisate, malonate, napsylate, edisylate, pamoate, xinafoate, napadisylate, hydrobromide, nitrate, oxalate, cinnamate, mandelate, undecylenate, and camsylate. Many of the compounds represented by Formula (I), Formula (Ia), Formula (II) and Formula (IIa) contain an acidic carboxylic acid moiety, in which case suitable pharma- ceutically acceptable salts thereof may include alkali metal salts (e.g., sodium or potassium salts); alkaline earth metal salts (e.g., calcium or magnesium salts); and salts formed with suitable organic ligands (e.g., quaternary ammonium salts).
[0086] The present invention includes within its scope the use of prodrugs of formula (I), formula (Ia), formula (II) and formula (IIa). In general, such prodrugs are functional derivatives of the compounds, which are easily converted in vivo to the required compound. Thus, in the treatment methods of the present invention, the term "administering" includes treating the various conditions described with a specifically disclosed compound or with a compound that converts in vivo to the specified compound after administration to a patient. Conventional methods for the selection and preparation of suitable prodrug derivatives are described, for example, in "Design of Prodrugs," ed. H. Bundgaard, Elsevier, 1985, which is incorporated herein by reference in its entirety. Metabolites of the compounds of formula (I), formula (Ia), formula (II) and formula (IIa) include active species produced when the compounds are introduced into a biological environment.
[0087] The term "administration" and variations thereof (e.g., "administering" a compound) refers to providing a particular compound (optionally in the form of its salt or hydrate) or a particular prodrug of that compound to a subject in need of treatment. When a compound of Formula (I), Formula (Ia), Formula (II) and Formula (IIa) or a pharma- ceutically acceptable salt or hydrate or prodrug thereof is provided in combination with a second active agent (e.g., another antifungal / antibacterial agent useful for treating fungal / bacterial infections), "administration" and variations thereof are understood to include simultaneous and sequential delivery of the compound (or its salt, hydrate or prodrug) and the other active agent, respectively.
[0088] As used herein, the term "composition" is intended to encompass products containing the identified ingredients, as well as any product that results directly or indirectly from combining the identified ingredients.
[0089] "Pharmaceutically acceptable" means that the components of a pharmaceutical composition must be compatible with each other and not deleterious to the recipient thereof.
[0090] The term "subject" (alternatively referred to herein as "patient"), as used herein, refers to an animal (preferably a mammal, most preferably a human) who has been the object of treatment, observation or experiment.
[0091] The term "effective amount" as used herein means an amount of an active ingredient or pharmaceutical agent that induces a biological or medical response in a tissue, system, animal or human that is being sought by a researcher, veterinarian, physician or other clinician. In one embodiment, an "effective amount" can be a "therapeutically effective amount" that alleviates the symptoms of the disease or condition being treated. In another embodiment, an "effective amount" can be a "prophylactically effective amount" that prevents or reduces the likelihood of developing the symptoms of the disease or condition being prevented. The term can also refer to an inhibitory effective amount of the enfumafungin derivative sufficient to inhibit (1,3)-β-D-glucan synthase and thereby induce the response being sought.
[0092] References to "treat," "treating," "treatment," and variations thereof generally refer to a treatment that, following administration, results in the elimination or amelioration of one or more signs or symptoms associated with a fungal infection, or that results in the eradication of the fungus causing the infection, or that results in any combination of these results.
[0093] For the purposes of treating and / or preventing PCP, the compounds of formula (I), formula (Ia), formula (II) or formula (IIa) (optionally in the form of a salt or hydrate) may be administered in any conventional manner available for use in combination with pharmaceutical agents.
[0094] For the purpose of treating and / or preventing PCP, the compounds of Formula (I), Formula (Ia), Formula (II) or Formula (IIa) (optionally in the form of a salt or hydrate) may be administered alone as an individual therapeutic agent or together (sequentially or simultaneously) with one or more additional antibacterial agents as a combination of therapeutic agents.
[0095] For the purposes of treating and / or preventing PCP, the compounds of Formula (I), Formula (Ia), Formula (II) or Formula (IIa) (optionally in the form of a salt or hydrate) can be administered with a pharmaceutical carrier selected on the basis of the chosen route of administration and standard pharmaceutical practice.
[0096] For example, the compounds of formula (I), formula (Ia), formula (II) and formula (IIa) and their pharma- ceutically acceptable salts and hydrate forms can be administered by one or more of the following routes: orally, parenterally (including subcutaneous injection, intravenous, intramuscular, intralesional injection or infusion techniques), by inhalation (e.g., nasal or buccal inhalation spray, aerosol from metered dose inhalers and dry powder inhalers), by nebulizer, ocularly, topically, transdermally, or rectally in the form of a unit dosage of a pharmaceutical composition containing an effective amount of the compound and conventional non-toxic pharma- ceutically acceptable carriers, adjuvants and vehicles. Liquid preparations suitable for oral administration (e.g., suspensions, syrups and elixirs, etc.) can be prepared according to techniques known in the art, and conventional vehicles such as water, glycols, oils and alcohols can be used. Solid preparations suitable for oral administration (e.g., powders, pills, capsules, and tablets) can be prepared according to techniques known in the art and can use solid excipients such as starches, sugars, kaolin, lubricants, binders, and disintegrants. Parenteral compositions can be prepared according to techniques known in the art and typically use sterile water as the carrier, and optionally other ingredients such as solubility aids. Injectable solutions can be prepared according to methods known in the art, where the carrier comprises saline, glucose solution, or a solution containing a mixture of saline and glucose.
[0097] Further description of suitable methods for use in preparing pharmaceutical compositions and suitable ingredients for use in such compositions can be found in Remington's Pharmaceutical Sciences, 20th edition, edited by AR Gennaro, Mack Publishing Co., 2000.
[0098] The compounds of formula (I), formula (Ia), formula (II) and formula (IIa) and their pharma- ceutically acceptable salts and hydrate forms can be administered, for example, orally or intravenously, in a dosage range of, for example, 0.001 to 1000 mg per kg of body weight of a mammal (e.g., human) per day, in a single dose or in divided doses. One example of a dosage range is 0.01 to 500 mg per kg of body weight per day, orally or intravenously, in a single dose or in divided doses. Another example of a dosage range is 0.1 to 50 mg per kg of body weight per day, orally or intravenously, in a single dose or in divided doses. For oral administration, the composition can be provided in the form of a tablet or capsule containing, for example, 1.0 to 1000 milligrams of active ingredient, particularly 1, 5, 10, 15, 20, 25, 50, 75, 100, 150, 200, 250, 300, 400, 500, 600, 750 and 1000 milligrams of active ingredient, to symptomatically adjust the dosage to the patient being treated. The specific dose level and frequency of administration for any particular patient can vary and will depend on a variety of factors, including the activity of the particular compound used, the metabolic stability and length of action of that compound, age, body weight, general health, sex, diet, method and time of administration, excretion rate, drug combination, severity of the particular condition, and treatments the host is undergoing. For example, in an embodiment, a pharma- ceutically acceptable salt of the compound of formula (IIa) is administered to a subject to provide a total daily dosage of the compound of formula (IIa) of 150 to 1500 mg. In certain embodiments, a total daily dose of 150 mg, or 250 mg, or 500 mg, or 750 mg, or 1000 mg, or 1500 mg of the compound of Formula (IIa) is administered; the total daily dose can be administered on a once-daily basis or can be divided, such as for BID (twice-daily) or TID (three times-daily) administration, or can be administered less frequently (e.g., three times a week, twice a week, or once a week), particularly for treating and / or preventing PCP.In embodiments, the pharma- ceutically acceptable salt of the compound of Formula (IIa) is administered QD (once per day) or BID to provide 150-750 mg of the compound of Formula (IIa) per day, or to provide 250-750 mg of the compound of Formula (IIa) per day, or to provide 250-1000 mg of the compound of Formula (IIa) per day.
[0099] In a preferred embodiment, the compound of Formula (IIa) or a pharma- ceutically acceptable salt or hydrate thereof is administered orally and provides a total daily dose of the compound of 250 mg to 1000 mg for treating Pneumocystis spp. pneumonia in a subject. In a preferred embodiment, the compound of Formula (IIa) or a pharma- ceutically acceptable salt or hydrate thereof is administered for 2 to 6 weeks for treating Pneumocystis spp. pneumonia in a subject.
[0100] In a preferred embodiment, the compound of formula (IIa) or a pharma- ceutically acceptable salt or hydrate thereof is administered orally and provides a total daily dose of the compound of 150 mg to 750 mg for preventing Pneumocystis spp. pneumonia in a subject. In a preferred embodiment, the compound of formula (IIa) or a pharma- ceutically acceptable salt or hydrate thereof is administered for 4 weeks or more for preventing Pneumocystis spp. pneumonia in a subject.
[0101] The antifungal activity of compounds against Pneumocystis spp. can be demonstrated by various assays known in the art, for example, by preventive or therapeutic models of Pneumocystis murina pneumonia in mice. The activity of compounds is typically assessed by measuring viability and pulmonary fungal burden, as indicated by quantitative assessment of cystic (aka asci) and vegetative (aka nuclei) forms of Pneumocystis in the lungs. Pneumocystis spp. cannot be cultured in vitro for a long enough time to allow for in vitro antifungal evaluation, and a mouse model of Pneumocystis infection is considered the best alternative. Pneumocystis spp. have species specificity depending on the mammal they infect. Pneumocystis jirovecii, the species responsible for infection in humans, does not efficiently infect mice. Pneumocystis murina is a mouse-specific species. Immunologic and physiopathological aspects of mouse models of PCP may be applicable to human infections.
[0102] The present invention provides a method of treating Pneumocystis spp. pneumonia in a subject, the method comprising administering to the subject a triterpenoid antifungal agent. In an embodiment, the triterpenoid antifungal agent is Ibrexafungerp. In an embodiment, the Pneumocystis spp. is P. jirovecii. In an embodiment, the Ibrexafungerp is administered orally. In an embodiment, both the nutrient burden and the cyst burden are reduced.
[0103] The present invention further provides a method of preventing Pneumocystis spp. pneumonia in a subject, the method comprising administering to the subject a triterpenoid antifungal agent. In an embodiment, the triterpenoid antifungal agent is Ibrexafungerp. In an embodiment, the Pneumocystis spp. is P. jirovecii. In an embodiment, the Ibrexafungerp is administered orally. In an embodiment, both the nutrient burden and the cyst burden are reduced. EXAMPLES
[0104] Working Example The following examples serve only to illustrate the invention and its practice and should not be construed as limitations on the scope or spirit of the invention.
[0105] Example 1 Evaluation of the efficacy of SCY-078 in a mouse model of prophylaxis against PCP The objective of this study was to evaluate the efficacy of orally administered SCY-078 (Ibrexafungelp) in preventing PCP, using standard of care TMP-SMX as a comparator.
[0106] Materials and Methods Preparation of compounds: SCY-078 (Ibrexafungelp) was prepared in 0.5% methylcellulose for oral administration. A correction factor of 1.37 for this lot was taken into account for salt and water content. Mice in the high dose group received 0.6 mg of SCY-078BID, mice in the mid dose group received 0.3 mg of SCY-078BID, and mice in the low dose group received 0.15 mg of SCY-078BID, based on an average mouse weight of 20 g.
[0107] Study design(s): The study groups were as follows: [Table 2]
[0108] Pneumocystis murina (P. murina) Prevention Study Methods: C3H / HeN mice (Charles River) were incubated with 2 × 10 6 Mice were infected by intranasal inoculation with P. murina organisms in 50 μL / ml. Prior to inoculation, the P. murina were preincubated overnight in RPMI 1640 medium supplemented with bovine serum and antibiotics to eliminate bacterial contamination. The immune system of the mice was suppressed by adding 4 mg / liter of dexamethasone to the acidified drinking water (1 mL / liter of hydrochloric acid). Acidification is used to prevent secondary microbial infection. The mice were divided into a negative (untreated) control group (control steroid - C / S), a positive control group (trimethoprim / sulfamethoxazole - TMP / SMX) and a treatment group. SCY-078 was administered orally (po) BID at the indicated doses. The prophylactic therapy was started at the same time the mice were inoculated. Immunosuppression and treatment continued throughout the 6-week study. At the end of the period, the mice were kept in a CO 2 Mice were euthanized at RT and lungs were processed for analysis by homogenization. Slides were prepared from various dilutions of lung homogenate and stained with Diff-Quik to quantify total nuclei (vegetative morphology) and cresyl ecto violet to quantify asci (cystic morphology).
[0109] Calculation: Efficacy was based on the reduction in organism burden between treatment and negative control groups, as determined by microscopic evaluation. Nuclei and asci numbers for each lung were log-transformed and statistical analysis was performed by analysis of variance (ANOVA); individual groups were compared by Student-Newman-Keuls t-test for multiple comparisons using GraphPad Prism. Statistical significance was accepted at a P value of ≦0.05.
[0110] result Figure 1 shows the log 10The mean nuclei and asci numbers are shown. C / S indicates vehicle treated negative control. TMP / SMX indicates trimethoprim / sulfamethoxazole. Brackets indicate statistically significant differences between treatment groups and C / S group. # indicates no statistically significant differences between treatment groups and TMP / SMX. Significance was accepted at a P value of ≦0.05.
[0111] As shown in Figure 1, prophylactic administration of SCY-078 resulted in a statistically significant reduction in both nuclei and asci when compared to untreated controls. There was a good dose-response relationship. The efficacy of the highest dose of SCY-078 was comparable to the gold standard, TMP / SMX.
[0112] Percent survival based on treatment group and week is shown in the table below, where * indicates a statistically significant difference between treatment and C / S groups. Although this model is not typically associated with high mortality, as shown in the table, the SCY-078 dosing regimen demonstrated better survival than untreated controls and was comparable to TMP / SMX. [Table 3]
[0113] conclusion All three doses of SCY-078 worked very well in this murine prophylactic model of P. murina pneumonia.
[0114] SCY-078 significantly reduced both nuclear and asci burdens at all three dose levels compared to the vehicle-treated negative control group (C / S).
[0115] At 30 mg / kg, SCY-078 performed as well as TMP / SMX, the gold standard for treatment of Pneumocystis pneumonia, in reducing ascus burden.
[0116] SCY-078, at 30 mg / kg, demonstrated a significant improvement in survival compared to the vehicle-treated negative control group.
[0117] In this PCP prevention model, SCY-078 demonstrated potent antifungal activity against both cystic and vegetative forms of P. murina.
[0118] SCY-078 represents a potentially practical prophylactic drug candidate for treating Pneumocystis pneumonia in humans.
[0119] Example 2 Evaluation of the effect of SCY-078 in a mouse model of treatment of PCP (early response) The objective of this study was to evaluate the efficacy of orally administered SCY-078 in the treatment of PCP, focusing on early time points of response (days 7, 14, and 21) using standard of care TMP / SMX as a comparator.
[0120] method Preparation of compounds: SCY-078 (Ibrexafungelp) was prepared in 0.5% methylcellulose for oral administration. A correction factor of 1.37 was taken into account for salt and water content. Mice in the high dose group received 0.3 mg Ibrexafungelp BID and mice in the low dose group received 0.1 mg Ibrexafungelp BID based on an average mouse weight of 20 g.
[0121] Study design(s): The study groups were as follows: [Table 4]
[0122] Pneumocystis murina (P. murina) Treatment Research Methods:C3H / HeN mice obtained from Charles River were infected with P. murina pneumonia by exposure to fulminant P. murina-infected mice (seed mice). These mice were immunosuppressed by adding 4 mg / liter dexamethasone to their drinking water. For disinfection, 1 mL / liter sulfuric acid was also added to the drinking water. The seed mice were rotated in their cages for 2 weeks and then removed. After the mice developed moderate levels of infection (approximately 5 weeks), they were divided into negative control (control steroid), positive control (TMP / SMX) and treatment groups. Test drugs were administered by oral gavage (PO) on a mg / kg / day basis for up to 3 weeks. At the end of treatment, the mice were immunized with CO 2 Mice were euthanized at RT and lungs were processed for analysis. Slides were prepared from various dilutions of lung homogenates and stained with Diff-Quik to quantify nuclei (all life cycle stages) and cresyl ecto violet to quantify asci.
[0123] Calculation: Efficacy was based on the reduction in organism burden between treatment and negative control groups, as determined by microscopic evaluation. Nuclei and asci numbers for each lung were log-transformed and statistical analysis was performed by analysis of variance (ANOVA); individual groups were compared by Student-Newman-Keuls t-test for multiple comparisons using GraphPad Prism. Statistical significance was accepted at a P value of ≦0.05.
[0124] result FIG. 2 shows the log 10 Mean nuclei and ascus numbers are shown. C / S indicates vehicle treated negative control. TMP / SMX indicates trimethoprim / sulfamethoxazole. Brackets indicate statistically significant differences between treatment groups and C / S group. # indicates statistically significant differences between treatment groups and TMP / SMX. Significance was accepted at a P value of ≦0.05.
[0125] As shown in Figure 2, SCY-078 at both dose levels significantly reduced ascus burden at the 14th and 21st day assessments compared to the vehicle-treated negative control group (C / S) and the degree of reduction was comparable to that of TMP / SMX, the gold standard for the treatment of Pneumocystis pneumonia. SCY-078 at both dose levels was statistically significantly superior to the gold standard TMP / SMX in reducing ascus burden at day 7. SCY-078 at both dose levels significantly reduced nucleus burden at the 14th and 21st day assessments compared to the vehicle-treated negative control group (C / S). The magnitude of the effect on nucleus burden, although lower than that observed with the TMP / SMX control, was significant when compared to the untreated control. Survival was observed in 90%-100% of all groups with no notable differences.
[0126] conclusion At both dose levels, SCY-078 performed significantly better in reducing ascus burden at day 7 than TMP / SMX, the gold standard for treatment of Pneumocystis pneumonia.
[0127] SCY-078 significantly reduced both nuclei and asci loads at both dose levels on days 14 and 21 compared to the vehicle-treated negative control group (C / S).
[0128] In this PCP treatment model, SCY-078 demonstrated potent antifungal activity against both cystic and vegetative forms of P. murina.
[0129] SCY-078 is a potentially viable therapeutic option for human Pneumocystis pneumonia.
[0130] Because no dose response was seen between the two arms of SCY-078, a study using a lower dose and longer follow-up period was approved.
[0131] Example 3 Evaluation of the Efficacy of SCY-078 in a Mouse Model for the Treatment of PCP The objective of this study was to evaluate the efficacy of orally administered SCY-078 in the treatment of PCP, using standard of care TMP / SMX as a comparator.
[0132] method Preparation of compounds: SCY-078 (Ibrexafungelp) was prepared in 0.5% methylcellulose for oral administration. A correction factor of 1.37 was taken into account for salt and water content. Mice in the high dose group received 0.3 mg Ibrexafungelp BID and mice in the low dose group received 0.1 mg Ibrexafungelp BID based on an average mouse weight of 20 g.
[0133] Study design(s): The study groups were as follows: [Table 5]
[0134] Pneumocystis murina (P. murina) Treatment Research Methods: Balb / c mice obtained from Charles River were infected with P. murina pneumonia by exposure to fulminant P. murina-infected mice (seed mice). These mice were immunosuppressed by adding 4 mg / liter dexamethasone to their drinking water. For disinfection, 1 mL / liter sulfuric acid was also added to the drinking water. The seed mice were rotated in their cages for 2 weeks and then removed. After the mice developed moderate levels of infection (approximately 5 weeks), they were divided into negative control (control steroid), positive control (TMP / SMX) and treatment groups. Test drugs were administered by oral gavage (PO) on a mg / kg / BID basis for up to 6 weeks. At the end of treatment, the mice were immunized with CO 2 The animals were euthanized at 4°C and the lungs were processed for analysis. Slides were prepared from various dilutions of lung homogenate and stained with Diff-Quik TMNuclei (all life cycle stages) were quantified by staining with and asci were quantified by staining with cresyl ecto violet.
[0135] Calculation: Efficacy was based on the reduction in organism burden between treatment and negative control groups, as determined by microscopic evaluation. Nuclei and asci numbers for each lung were log-transformed and statistical analysis was performed by analysis of variance (ANOVA); individual groups were compared by Student-Newman-Keuls t-test for multiple comparisons using GraphPad Prism. Statistical significance was accepted at a P value of ≦0.05.
[0136] result FIG. 3 shows the log 10 The mean nuclei and asci numbers are shown. C / S indicates vehicle treated negative control. TMP / SMX indicates trimethoprim / sulfamethoxazole. Brackets indicate statistically significant differences between treatment groups and C / S group. * indicates no statistically significant differences between treatment groups and TMP / SMX. Significance was accepted at a P value of ≦0.05.
[0137] As shown in Figure 3, SCY-078 at all dose levels significantly reduced both nuclei and asci loads at all three time points compared to the vehicle-treated negative control group (C / S).
[0138] Survival rates were between 90% and 100% for all SCY-078 and TMP / SMX treatment groups on days 28, 35, and 42, with no statistical differences in survival observed.
[0139] conclusion SCY-078 at all dose levels significantly reduced both nuclei and asci loads at all three time points compared to the vehicle-treated negative control group (C / S).
[0140] SCY-078 at all dose levels performed as well as the positive control (TMP / SMX) in reducing ascus burden on day 42. On days 28 and 35, the 15 mg / kg and 10 mg / kg groups performed as well as the positive control in reducing ascus burden.
[0141] No asci were observed in the 15 mg / kg and 10 mg / kg groups on days 28 and 35. However, some asci were observed in all three dose groups on day 42.
[0142] There were no statistical differences in survival rates between the active treatment groups at any time point.
[0143] In this PCP treatment model, SCY-078 demonstrated potent antifungal activity against both cystic and vegetative forms of P. murina.
[0144] SCY-078 is a potentially viable therapeutic option for human Pneumocystis pneumonia.
[0145] While the present invention has been shown and described with particular reference to preferred embodiments thereof, those skilled in the art will recognize in light of this disclosure that various changes in form and detail can be made therein without departing from the scope of the invention as encompassed by the appended claims.
Claims
1. 1. A pharmaceutical composition for a method of treating Pneumocystis pneumonia in a subject in need thereof, comprising a compound of formula (II): 【Chemistry 1】 (which is (1S,4aR,6aS,7R,8R,10aR,10bR,12aR,14R,15R)-15-[[2-amino-2,3,3-trimethylbutyl]oxy]-8-[(1R)-1,2-dimethylpropyl]-14-[5-(4-pyridinyl)-1H-1,2,4-triazol-1-yl]-1,6,6a,7,8,9,10,10a,10b,11,12,12a-dodecahydro-1,6a,8,10a-tetramethyl-4H-1,4a-propano-2H-phenanthro[1,2-c]pyran-7-carboxylic acid) or a pharma- ceutical composition comprising ...
2. 2. The pharmaceutical composition of claim 1, wherein the Pneumocystis pneumonia is caused by Pneumocystis jirovecii.
3. 3. The pharmaceutical composition of claim 2, wherein the method reduces the cystic and nutrient burden of Pneumocystis jirovecii.
4. 4. The pharmaceutical composition according to any one of claims 1, 2 and 3, wherein said method comprises administering said compound or a pharma- ceutically acceptable salt or hydrate thereof orally.
5. 4. The pharmaceutical composition according to any one of claims 1, 2 and 3, wherein said method comprises administering said compound or a pharma- ceutically acceptable salt or hydrate thereof intravenously.
6. The pharmaceutical composition of any one of claims 1, 2, 3, 4 and 5, wherein the subject is a human.
7. 1. A pharmaceutical composition for a method of treating Pneumocystis jirovecii pneumonia in a human in need thereof, comprising a compound of formula (IIa): 【Chemistry 3】 (which is (1S,4aR,6aS,7R,8R,10aR,10bR,12aR,14R,15R)-15-[[(2R)-2-amino-2,3,3-trimethylbutyl]oxy]-8-[(1R)-1,2-dimethylpropyl]-14-[5-(4-pyridinyl)-1H-1,2,4-triazol-1-yl]-1,6,6a,7,8,9,10,10a,10b,11,12,12a-dodecahydro-1,6a,8,10a-tetramethyl-4H-1,4a-propano-2H-phenanthro[1,2-c]pyran-7-carboxylic acid) or a pharma- ceutical composition comprising ...
8. 8. The pharmaceutical composition of claim 7, wherein the method reduces the cystic and nutrient burden of Pneumocystis jirovecii.
9. 9. The pharmaceutical composition according to any one of claims 7 and 8, wherein said method comprises administering said compound or a pharma- ceutically acceptable salt or hydrate thereof orally.
10. 9. The pharmaceutical composition according to any one of claims 7 and 8, wherein said method comprises administering said compound or a pharma- ceutically acceptable salt or hydrate thereof intravenously.
11. 11. The pharmaceutical composition of any one of claims 7, 8, 9 and 10, wherein the method comprises administering a citrate salt of the compound of formula (IIa).
12. 10. The pharmaceutical composition according to any one of claims 7, 8 and 9, wherein the method comprises administering orally the pharma- ceutically acceptable salt of the compound of formula (IIa) in a tablet.
13. 8. The pharmaceutical composition of claim 7, wherein said method comprises administering said compound, or a pharma- ceutically acceptable salt or hydrate thereof, orally and providing a total daily dosage of said compound of from 250 mg to 1000 mg.
14. The pharmaceutical composition of claim 7, wherein said method comprises administering said compound or a pharma- ceutically acceptable salt or hydrate thereof for a period of 2 to 6 weeks.
15. 1. A pharmaceutical composition for a method of treating Pneumocystis jirovecii pneumonia in a human in need thereof, comprising a compound of formula (IIa): 【Chemistry 5】 (which is (1S,4aR,6aS,7R,8R,10aR,10bR,12aR,14R,15R)-15-[[(2R)-2-amino-2,3,3-trimethylbutyl]oxy]-8-[(1R)-1,2-dimethylpropyl]-14-[5-(4-pyridinyl)-1H-1,2,4-triazol-1-yl]-1,6,6a,7,8,9,10,10a,10b,11,12,12a-dodecahydro-1,6a,8,10a-tetramethyl-4H-1,4a-propano-2H-phenanthro[1,2-c]pyran-7-carboxylic acid).
16. 16. The pharmaceutical composition of claim 15, comprising a citrate salt of the compound of formula (IIa).
Citation Information
Patent Citations
Method for inhibiting pneumocystis carinii
JP1990288837A
Antifungal agent obtained from hormonema
US5756472A
Antifungal agents
WO2007126900A2
Antifungal agents
WO2007127012A1
Antifungal agents with enhanced activity in acidic ph
WO2019028034A1
